IAG is pleased to announce several publications at the upcoming EULAR 2023 conference. These publications represent IAG’s ongoing commitment to advancing the field of rheumatology through innovative research and collaboration. Join our team and collaborators who will be discussing the value of novel scoring system to improve clinical trials’ outcomes.

“Today, clinical trials require designs and endpoints which can give quick definitive answers about novel treatments in smaller patient cohorts and allow determining competitive edge of a novel drug candidate,” said Olga Kubassova, CEO and co-founder of IAG. “This is a great opportunity to showcase our research and support biotech and pharma collaborators.”

Below is a list of posters and presentations:

• MRI Digital Artery Volume Index (DAVIX©) as quantitative, continuous imaging outcome measure of vascular disease in systemic sclerosis – Poster: POS1336

 

• Efficacy of Apremilast on Whole-Body Inflammation Indices in Patients With Psoriatic Arthritis: Assessments by Whole-Body Magnetic Resonance Imaging in the Phase 4 MOSAIC Study – Publication: AB1535

 

• Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study – Poster: POS0226

 

• A Proof of Biological Concept Trial of CM101 to Target CCL24 in Systemic Sclerosis: a Biomarker Informed, Precision Medicine Approach – Publication: AB0808

 

• A Phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in subjects with symptomatic knee osteoarthritis – Poster: POS0104

 

• Five-Year Follow-Up Of A 2-Year Mri Treat-To-Target Strategy On Radiographic Damage Progression In Rheumatoid Arthritis Patients In Clinical Remission – The Imagine-More Study – Poster: POS0052

 

• Intra-Articular Mm-Ii, A Novel Suspension Of Large Empty Multilamellar Liposomes, In Painful Knee Osteoarthritis: A 26 Week Phase 2b Randomized Trial – Poster: POS0106

 

• The Influence Of Baseline Demographics On Variability Of Oa Pain Assessed By Womac Pain Change From Baseline In Interventional Trials – Poster:POS1361

 

• Colchicine Twice Daily For Hand Osteoarthritis: Results From The Double-Blind, Randomised, Placebo-Controlled Color Trial – Presentation: OP0073 

 

• 2023 Update Of Eular Recommendations For The Treatment Of Systemic Sclerosis – Presentation: OP0234

We will provide further updates on the specific details of these publications as they become available.

“It is important to us that our work is accessible to the broader scientific community,” said Prof. Mikael Boesen, chair of Scientific Advisory Board of IAG.

IAG looks forward to participating in EULAR 2023 and contributing to the ongoing advancement of the field of rheumatology.

Join IAG’s scientific team at EULAR 2023, May 30 – June 2 2023, Milan, Italy, at our poster presentations!

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

At the DDW next week, IAG’s team will join the discussions about the value of pathology in Ulcerative Colitis and its ability to predict the disease severity and outcomes.

Our 2 presentations, with scientific and industry collaborators cover real-world AI deployment for gastroenterology clinical research and predictive nature of AI Histology in drug development.

IAG, Image Analysis Group, a leader in the field of IA and quantitative imaging for drug development, working across many therapeutic areas.

We deploy AI, our platform DYNAMIKA and global operations to extract meaningful insights from the imaging in clinical trials. We support phase 1-3 trials and special data mining projects, working in partnership with biotech and pharma companies. Examples and case studies of our work are available here: wp1.ia-grp.com

 

IAG’s team and collaborators will present 2 posters at Digestive Disease Week 2023 (DDW2023)

1: DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES –  Session date: May 7, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with Takeda Pharmaceuticals and a global panel of gastroenterology and pathology experts support the deployment of AI in gastroenterology practice. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting dataset generated over 43,000 characterisations that were used to further train the AI Tool in the segmentation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.

2: A NOVEL AI TOOL IS ACCURATE AT INTERPRETING HISTOLOGY AND DETECTS RESPONSE TO NEIHULIZUMAB THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: PROOF OF CONCEPT – Session date: May 8, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with AltruBio Inc and David T. Rubin MD, report in this abstract the conduct an AI driven retrospective analysis of digitised histology biopsy slides from AltruBio’s Phase IIb study of Neihulizumab (NCT03298022), a novel immune checkpoint agonistic antibody that binds to human CD162 that is being tested in UC and graft versus host disease. Quantitative analyses of cell and tissue types were performed longitudinally at screening and week 12 after 10 doses of Neihulizumab. Results reveal a correlation between disease remission and reduced neutrophil density. AI generated disease stage scores reported using the Nancy Index correlated well (87%) with human readers of the same biopsies.

---

Join IAG’s scientific team at DDW 2023, March 6-9 2023, Chicago, USA, at our poster presentations!

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

IAG’s team and collaborators will present 2 posters at Digestive Disease Week 2023 (DDW2023)

1: DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES –  Session date: May 7, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with Takeda Pharmaceuticals and a global panel of gastroenterology and pathology experts support the deployment of AI in gastroenterology practice. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting dataset generated over 43,000 characterisations that were used to further train the AI Tool in the segmentation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.

2: A NOVEL AI TOOL IS ACCURATE AT INTERPRETING HISTOLOGY AND DETECTS RESPONSE TO NEIHULIZUMAB THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: PROOF OF CONCEPT – Session date: May 8, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with AltruBio Inc and David T. Rubin MD, report in this abstract the conduct an AI driven retrospective analysis of digitised histology biopsy slides from AltruBio’s Phase IIb study of Neihulizumab (NCT03298022), a novel immune checkpoint agonistic antibody that binds to human CD162 that is being tested in UC and graft versus host disease. Quantitative analyses of cell and tissue types were performed longitudinally at screening and week 12 after 10 doses of Neihulizumab. Results reveal a correlation between disease remission and reduced neutrophil density. AI generated disease stage scores reported using the Nancy Index correlated well (87%) with human readers of the same biopsies.

---

“IAG are pleased to collaborate with world recognised opinion leaders to leverage IAG’s advanced imaging capabilities as we study the potential of AI driven histology to benefit patients with Ulcerative Colitis,” said Dr Olga Kubassova, CEO of IAG, Image Analysis Group.

Join IAG’s scientific team at DDW 2023, March 6-9 2023, Chicago, USA, at our poster presentations!

Mucosal healing is an established treatment target in UC, but not all clinical sites have access to the required resources. The AI Tool has the potential to facilitate rapid, detailed histological assessment in a clinical setting for the benefit of all UC patients” said Simon Hart, Director, Biopartnering, Image Analysis Group.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

IAG’s team and collaborators will present at the European Crohn’s and Colitis Organisation Congress 2023 (ECCO 2023)

Deployment of an Artificial Intelligence Tool for Precision Medicine in Ulcerative Colitis: Preliminary Data from 8 Globally Distributed Clinical Sites

Presentation number: P777
Session date: Friday, March 3, 2023
Session time: 12:30 – 13:30

Scientific advisors and collaborators from gastroenterology and pathology departments include:

• Nancy University Hospital, Gastroenterology, Nancy, France,
• University of Chicago Medicine, Section of Gastroenterology Hepatology and Nutrition, Chicago- IL, United States,
• University Hospital of Zurich, University of Zürich, Zurich, Switzerland,
• University of British Columbia, Division of Gastroenterology, Vancouver- BC, Canada,
• University of Basel, University Hospital Basel, Basel, Switzerland,
• Chaim Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel,
• Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal,
• Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel

IAG‘s team together with Takeda Pharmaceutical support the deployment of AI in gastroenterology practices. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting data set generated over 43,000 characterisations that were used to further train the AI Tool in the characterisation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.

We are pleased to collaborate with world recognised opinion leaders to leverage IAG’s advanced imaging capabilities as we study the potential of AI driven histology to benefit patients with Ulcerative Colitis, said Dr Olga Kubassova, CEO of IAG, Image Analysis Group.

Join IAG’s scientific team at ECCO 2023, March 1-4 2023, Copenhagen, Denmark, at our poster presentation!

Mucosal healing is an established treatment target in UC, but not all clinical sites have access to the required resources. The AI Tool has the potential to facilitate rapid, detailed histological assessment in a clinical setting for the benefit of all UC patients’ said Simon Hart, Biopartnering Director, Image Analysis Group.

 

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Lisbon, Portugal and London, UK, 8 February 2023

TargTex to partner with IAG to apply Artificial Intelligence and Advanced Imaging strategies to assess the effects of a clinical candidate in Recurrent Glioblastoma Patients

TargTex SA, a pre-clinical stage biopharmaceutical company focused on developing localized therapies for solid  tumors and IAG, Image Analysis Group, a leading global medical imaging company are collaborating to apply Artificial Intelligence (AI) and Quantitative imaging to further the development of TargTex investigational product, a hydrogel dispersed drug nanosuspension used as adjunct-to-surgery in a single dose therapy, in patients with glioblastoma multiforme (GBM).

In this collaboration, the parties will utilize AI and advanced quantitative image analysis to identify early treatment changes in GBM patients and development of predictive response markers.

Advanced imaging techniques could play a critical role in response assessment in developing new and innovative cancer therapies. Multiparametric magnetic resonance imaging (mpMRI) provides quantitative non-invasive imaging markers of early therapy-related changes.

TargTex foundation is also based on an artificial intelligence algorithm created by one of the founding members that can decipher relationships between biological targets and molecules of interest. They were able to identify an unexplored target for a daunting pathology – GBM. Considering GBM’s particularities, a hydrogel to be used as neo-adjuvant in a single dose therapy is being developed as a solution.

IAG’s advanced technology will be crucial for detection of pseudo-progression which is difficult to distinguish from true disease progression using routine clinical MRI assessment, avoid early patient withdrawal and save costs. The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG has deep expertise in blinded centralized reading and analysis of patient responses in real time. IAG’s scientific and medical imaging expertise in GBM, coupled with IAG’s proprietary Artificial Intelligence powered platform DYNAMIKA will allow TargTex to review efficacy assessments, and to thoroughly explore the drug effect in GBM patients.

Dr. João Seixas, CEO of TargTex, said:

“In a complex indication such as GBM it is important for us to have IAG’s expertise in advanced imaging and to employ AI tools to differentiate our program and accelerate our development through the use of predictive response markers.”

Dr. Olga Kubassova, CEO of IAG commented,

“It is our pleasure to support TargTex team who have strong foundation in biology and AI. It is our joint long-term objective to bring TargTex clinical candidates for different oncological indications through clinical development to commercialization.”

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, fluoroscopy, PET, immunoPET, SPECT, US, histology, and DXA imaging.

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

 

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s DNA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘IAG brings artificial intelligence in a meaningful way to the imaging process. This is the future of imaging – drives down cost and improves quality of analysis.  As images are used more for statistically meaningful endpoints, IAG has proven, validated, AI algorithms. The IAG platform and service model fits exactly with pharma efforts to be digital organizations, allowing seamless data ingestion capabilities and real time data access for analysis and decision making.’, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s NDA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘We see DYNAMIKA as a unique bridge between clinical trials and clinical practice worlds. It is not trivial to translate the results of clinical trials into clinical practice. Here at IAG, we can power our pharmaceutical partners to do just that, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin